Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Krka DDFRA:KN8 +3.07%61 Days Inventory is 247.10 as of Mar. 2026, which is 1% above its 10-year median of 243.78. GuruFocus rates FRA:KN8 with a GF Score™ of 61/100 and a GF Value™ of €148.66 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 923 Drug Manufacturers companies, Krka DD ranks worse than 77.25% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). Krka DD's Average Total Inventories for the
three
months ended in Mar. 2026 was €606 Mil. Krka DD's Cost of Goods Sold for the
three
months ended in Mar. 2026 was €224 Mil.
Hence, Krka DD's Days Inventory for the
three
months ended in Mar. 2026 was 247.10.
The historical rank and industry rank for Krka DD's Days Inventory or its related term are showing as below:
FRA:KN8'
s Days Inventory Range Over the Past 10 Years
Min: 183.96 Med: 243.78 Max: 264.92
Current: 258.61
During the past 13 years, Krka DD's highest Days Inventory was 264.92. The lowest was 183.96. And the median was 243.78.
FRA:KN8's Days Inventory is ranked worse than 77.25% of 923
companies
in the Drug Manufacturers industry
Industry Median: 164.38
vs FRA:KN8: 258.61
Krka DD's Days Inventory
declined
from Mar. 2025 (258.32) to Mar. 2026 (247.10).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Krka DD's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.37.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Krka DD's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 1.07.
Krka DD (FRA:KN8) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Krka DD's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Krka DD's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Krka DD Days Inventory Related Terms
Krka DD Days Inventory Historical Data
* Premium members only.
The historical data trend for Krka DD's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:KN8 vs ZTS, UTHR, VTRS: Days Inventory Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Krka DD's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Krka DD Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Krka DD's Days Inventory distribution charts can be found below:
* The bar in red indicates where Krka DD's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Krka DD (FRA:KN8) has a Days Inventory of 247.10 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Krka DD and its competitors. This is near median its historical median of 243.78. Over the past decade, Krka DD's Days Inventory has ranged from 183.96 to 264.92. According to the industry distribution chart, Krka DD ranks #713 out of 923 companies in the Drug Manufacturers industry, placing it in the top 77.2%.
Is Krka DD's Days Inventory too high?
Krka DD's current Days Inventory of 247.10 is near median its 10-year median of 243.78. Over the past 10 years, this metric has ranged from a low of 183.96 to a high of 264.92. The Drug Manufacturers industry median Days Inventory is 164.38. Krka DD's value of 247.10 is 50.3% above this industry median. Based on the distribution chart, Krka DD ranks #713 out of 923 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Krka DD has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Krka DD's Days Inventory compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Krka DD ranks #713 out of 923 companies for Days Inventory. This places Krka DD in the lower half of its industry. The industry median Days Inventory is 164.38. Krka DD's value of 247.10 is 50.3% above this benchmark. Historically, Krka DD's own Days Inventory has ranged from 183.96 to 264.92 over the past decade. While the company's 10-year median is 243.78 vs. the industry median of 164.38, Krka DD has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.38, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Krka DD's current Days Inventory of 247.10 is 50.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Krka DD and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Krka DD's current Days Inventory is 247.10, which is near median its own 10-year median of 243.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krka DD stock overvalued right now?
Based on GuruFocus' analysis, Krka DD (FRA:KN8) is currently considered Significantly Overvalued. The stock's GF Value™ is €148.66, compared to a current price of €269.00 — trading 80.9% above its estimated fair value. The current Days Inventory is 247.10, which is near median its 10-year median of 243.78 and 50.3% above the Drug Manufacturers industry median of 164.38. Krka DD's overall GF Score™ is 61/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Krka DD (FRA:KN8), the current Days Inventory is 247.10 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Krka DD (FRA:KN8) Overvalued in 2026?
Based on GuruFocus' analysis, Krka DD stock appears to be overvalued.
The current stock price of €269.00 is trading 80.9% above its estimated GF Value™ of €148.66.
GuruFocus considers Krka DD to be Significantly Overvalued.
Key valuation signals for FRA:KN8:
Days Inventory: 247.10 (near median its 10-year median of 243.78)
GF Value™: €148.66 vs. price of €269.00 (80.9% above fair value)
Industry Position: 50.3% above the Drug Manufacturers median (#713 of 923)
No single metric tells the full story. See the FRA:KN8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Krka DD engages in the development, production, marketing, and sales of human health products (prescription pharmaceuticals and non-prescription products), animal health products, health resorts, and tourist services. The company's products in Prescription pharmaceuticals include Cardiovascular diseases, Infections, and Oncology; Non-prescription products include Cold and cough products, nasal products, vitamins and minerals, and hair care products; and Animal health products include Antimicrobials and disinfectants, among others. It operates across the European Union, South-East Europe, Eastern Europe region, and Others. The company derives a majority of its revenue from the European Union.
61GF Score
Get the complete analysis for FRA:KN8
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:KN8 has been successfully added to your 
